Annual report pursuant to Section 13 and 15(d)

Income Taxes (Tables)

v3.22.4
Income Taxes (Tables)
12 Months Ended
Dec. 31, 2022
Income Tax Disclosure [Abstract]  
Schedule of deferred tax assets
    As of December 31,  
    2022     2021  
Current:            
Accrued expenses   $ 133,591     $ 144,077  
                 
Stock compensation     354,274       1,800,762  
                 
Net operating loss carryforward     20,980,803       19,481,137  
                 
Research and development credit carry forward     1,340,317       252,536  
                 
Capitalized research and development     1,419,818      
-
 
                 
Total deferred tax assets     24,228,803       21,678,512  
                 
Valuation allowance     (24,228,803 )     (21,678,512 )
                 
Deferred tax asset, net of valuation allowance   $
-
    $
-
 

 

Schedule of federal income tax rate to effective tax rate
    For the Years Ended December 31,  
    2022     2021  
U.S. statutory federal rate     21.0 %     21.0 %
State income taxes, net of federal tax     7.1 %     7.0 %
Permanent differences     0.1 %     (2.5 )%
Prior year true-ups     (10.9 )%     (2.7 )%
R&D tax credit     3.7 %     0.1 %
Change in valuation allowance     (21.0 )%     (22.9 )%
Income tax provision (benefit)    
-
%    
-
%

 

Schedule of income tax provision consists
    For the Years Ended
December 31,
 
    2022     2021  
Federal            
Current   $
-
    $
-
 
Deferred     (1,909,246 )     (2,723,112 )
State and local                
Current    
-
     
-
 
Deferred     (641,044 )     (905,577 )
Change in valuation allowance     2,550,290       3,628,689  
Income tax provision (benefit)   $
-
    $
-